NVCR — NovoCure Ltd
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1645113 ·
Jersey
Last close
$17.78
Market Cap
$2.06B
52W High
$18.92
52W Low
$10.14
ADV30
1,651,343
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 174,055,000 | 135,126,000 | -67,420,000 | -71,138,000 | 787,926,000 | 87,527,000 | 457,209,000 |
| Dec 2025 | 174,350,000 | 132,193,000 | -40,393,000 | -24,499,000 | 804,326,000 | 93,548,000 | 463,860,000 |
| Sep 2025 | 167,204,000 | 122,475,000 | -36,021,000 | -37,270,000 | 1,361,194,000 | 342,119,000 | 1,019,861,000 |
| Jun 2025 | 158,805,000 | 117,333,000 | -39,521,000 | -40,139,000 | 1,245,875,000 | 149,624,000 | 896,434,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,883,000
Investing CF
$451,495,000
Financing CF
$-456,756,000
CapEx
$-21,189,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,361,495,000
Inventory
$43,458,000
Receivables
$146,404,000
ST Investments
$344,477,000
EBIT TTM
$-148,768,000
Pretax Income TTM
$-175,213,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$674,414,016
EBITDA
$-166,215,008
Free Cash Flow
$5,082,750
Enterprise Value
$1,862,232,320
Total Cash
$432,004,000
Total Debt
$234,940,000
Shares Out
115,820,940
Trailing EPS
$-1.53
Book Value
$2.85
ROE
-50.0%
ROA
-11.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 655,353,000 | -153,800,000 | -136,227,000 | 804,326,000 | 463,860,000 | — | -49,031,000 |
| Dec 2024 | 605,220,000 | -170,496,000 | -168,627,000 | 1,240,784,000 | 880,605,000 | — | -26,369,000 |
| Dec 2023 | 509,338,000 | -232,870,000 | -207,043,000 | 1,146,129,000 | 783,633,000 | — | -73,336,000 |
| Dec 2022 | 537,840,000 | -89,523,000 | -92,534,000 | 1,191,648,000 | 750,478,000 | — | 30,788,000 |
TTM Snapshot
Revenues TTM
$547,020,000
NetIncome TTM
$-119,755,000
OpCashFlow TTM
$0
Assets (Latest)
$1,240,784,000
Forward EPS
$-1.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XRAY | DENTSPLY SIRONA Inc. | $2.02B | $10.09 | — |
| LMAT | LEMAITRE VASCULAR INC | $2.10B | $91.96 | — |
| AXGN | Axogen, Inc. | $2.29B | $43.00 | — |
| UFPT | UFP TECHNOLOGIES INC | $1.82B | $234.94 | — |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.42B | $82.14 | — |
News headlines (Yahoo Finance, 1h cache)
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing
2026-06-09 14:32 · Yahoo
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
2026-06-09 10:21 · Yahoo
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)
2026-06-08 16:13 · Yahoo
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
2026-05-30 18:59 · Yahoo
3 Overlooked Stocks Set to Soar in 2026
2026-05-05 13:05 · Yahoo
NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry
2026-05-04 20:25 · Yahoo
International Markets and NovoCure (NVCR): A Deep Dive for Investors
2026-05-04 13:15 · Yahoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
2026-05-02 13:13 · Yahoo
NovoCure Limited Q1 2026 Earnings Call Summary
2026-05-01 00:45 · Yahoo
NovoCure (NVCR) Q1 2026 Earnings Transcript
2026-04-30 21:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.